These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38637505)

  • 1. Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.
    Yamagata A; Ito K; Suzuki T; Dohmae N; Terada T; Shirouzu M
    Nat Commun; 2024 Apr; 15(1):3027. PubMed ID: 38637505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers.
    Finnema SJ; Rossano S; Naganawa M; Henry S; Gao H; Pracitto R; Maguire RP; Mercier J; Kervyn S; Nicolas JM; Klitgaard H; DeBruyn S; Otoul C; Martin P; Muglia P; Matuskey D; Nabulsi NB; Huang Y; Kaminski RM; Hannestad J; Stockis A; Carson RE
    Epilepsia; 2019 May; 60(5):958-967. PubMed ID: 30924924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
    Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
    Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
    Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
    Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Gillard M
    Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
    Wood MD; Sands ZA; Vandenplas C; Gillard M
    Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
    Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brivaracetam augments short-term depression and slows vesicle recycling.
    Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
    Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy.
    Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM
    Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug characteristics derived from kinetic modeling: combined
    Naganawa M; Gallezot JD; Finnema SJ; Maguire RP; Mercier J; Nabulsi NB; Kervyn S; Henry S; Nicolas JM; Huang Y; Chen MK; Hannestad J; Klitgaard H; Stockis A; Carson RE
    EJNMMI Res; 2022 Nov; 12(1):71. PubMed ID: 36346513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2.
    Liu Z; Lee PG; Krez N; Lam KH; Liu H; Przykopanski A; Chen P; Yao G; Zhang S; Tremblay JM; Perry K; Shoemaker CB; Rummel A; Dong M; Jin R
    Nat Commun; 2023 Apr; 14(1):2338. PubMed ID: 37095076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
    Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
    Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors.
    Azzaz F; Hilaire D; Fantini J
    Chem Biol Interact; 2023 Mar; 373():110384. PubMed ID: 36754227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.
    Dong M; Liu H; Tepp WH; Johnson EA; Janz R; Chapman ER
    Mol Biol Cell; 2008 Dec; 19(12):5226-37. PubMed ID: 18815274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synaptic vesicle protein 2A tumoral expression predicts levetiracetam adverse events.
    Romoli M; Mandarano M; Romozzi M; Eusebi P; Bedetti C; Nardi Cesarini E; Verzina A; Calvello C; Loreti E; Sidoni A; Giovenali P; Calabresi P; Costa C
    J Neurol; 2019 Sep; 266(9):2273-2276. PubMed ID: 31168673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brivaracetam for the treatment of epilepsy.
    Schulze-Bonhage A
    Expert Opin Pharmacother; 2011 Aug; 12(12):1959-66. PubMed ID: 21682662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brivaracetam: a novel antiepileptic drug for focal-onset seizures.
    Stephen LJ; Brodie MJ
    Ther Adv Neurol Disord; 2018; 11():1756285617742081. PubMed ID: 29399049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil.
    Wu PP; Cao BR; Tian FY; Gao ZB
    Neurosci Bull; 2024 May; 40(5):594-608. PubMed ID: 37897555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural Basis of Botulinum Toxin Type F Binding to Glycosylated Human SV2A:
    Azzaz F; Hilaire D; Fantini J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study.
    Asadi-Pooya AA; Sperling MR; Chung S; Klein P; Diaz A; Elmoufti S; Schiemann J; Whitesides J
    Epilepsy Res; 2017 Mar; 131():70-75. PubMed ID: 28279891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.